RVL Pharmaceuticals plc Annual Share-based Payment Arrangement, Expense in USD from 2018 to 2022

Taxonomy & unit
us-gaap: USD
Description
Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.
Summary
RVL Pharmaceuticals plc quarterly/annual Share-based Payment Arrangement, Expense history and growth rate from 2018 to 2022.
  • RVL Pharmaceuticals plc Share-based Payment Arrangement, Expense for the quarter ending June 30, 2023 was $232K, a 80.8% decline year-over-year.
  • RVL Pharmaceuticals plc Share-based Payment Arrangement, Expense for the twelve months ending June 30, 2023 was $2.21M, a 68.4% decline year-over-year.
  • RVL Pharmaceuticals plc annual Share-based Payment Arrangement, Expense for 2022 was $3.9M, a 42.6% decline from 2021.
  • RVL Pharmaceuticals plc annual Share-based Payment Arrangement, Expense for 2021 was $6.8M, a 51.1% increase from 2020.
  • RVL Pharmaceuticals plc annual Share-based Payment Arrangement, Expense for 2020 was $4.5M, a 12.5% increase from 2019.
Share-based Payment Arrangement, Expense, Trailing 12 Months (USD)
Share-based Payment Arrangement, Expense, Annual (USD)
Share-based Payment Arrangement, Expense, YoY Annual Growth (%)
Period Value YoY Chg Change % Start Date End Date Report Filed
2022 $3.9M -$2.9M -42.6% Jan 1, 2022 Dec 31, 2022 10-K 2023-03-20
2021 $6.8M +$2.3M +51.1% Jan 1, 2021 Dec 31, 2021 10-K 2023-03-20
2020 $4.5M +$500K +12.5% Jan 1, 2020 Dec 31, 2020 10-K 2022-03-30
2019 $4M +$2M +100% Jan 1, 2019 Dec 31, 2019 8-K 2021-09-08
2018 $2M Jan 1, 2018 Dec 31, 2018 10-K 2020-03-19
* An asterisk sign (*) next to the value indicates that the value is likely invalid.